Omeros’ OMS302 reduces incidence of miosis during intraocular lens replacement in Phase 3 clinical trial

Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.

Full Story →